Trial NCT01736579

View at ClinicalTrials.gov 
Org. Study IDs: 161202

Last trial update was posted on 2021-05-19

MeSH Interventions

Antibodies Immunoglobulins Immunoglobulins, Intravenous Rho(D) Immune Globulin gamma-Globulins

MeSH Conditions

Alzheimer Disease

Other Conditions

Alzheimer´s Disease

Stopping Reasons

The study was terminated because the first Phase 3 did not demonstrate efficacy on the co-primary endpoints. The known safety profile remained unchanged.

Limitations And Caveats

This study was an extension of study 160701 and was stopped early due to lack of evidence of clinical benefit of IGIV treatment in Alzheimer's Disease patients in Baxalta study 160701. Summary tables available for safety data only.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID